MR弹性成像测量的肿瘤硬度评估肝细胞癌对局部区域治疗反应的价值
回顾性纳入52例接受钇-90放射栓塞(22例)或经动脉化疗栓塞联合射频消融(30例)的肝细胞癌患者及11例未治疗对照,用2D MRE测量肿瘤硬度。治疗后肿瘤硬度显著低于未治疗肿瘤(3.9±1.8 vs 6.9±3.4 kPa,p=0.006),且与强化比(r=0.514)和坏死百分比(r=-0.540)显著相关,放射栓塞组相关性更强。
要点
- 治疗后肝细胞癌MRE肿瘤硬度显著低于未治疗肿瘤(3.9±1.8 vs 6.9±3.4 kPa,p=0.006)。
- 肿瘤硬度与强化比正相关(r=0.514)、与坏死百分比负相关(r=-0.540)。
- 放射栓塞组肿瘤硬度与强化比(r=0.636)及坏死百分比(r=-0.711)相关性更强。
核心结论
- MRE测量的肿瘤硬度与肿瘤强化和坏死显著相关,在经放射栓塞治疗的肝细胞癌中尤为明显。
研究设计与样本
- 回顾性研究,经IRB批准并豁免知情同意;纳入52例肝细胞癌患者(男/女38/14,平均年龄67岁),其中放射栓塞22例、经动脉化疗栓塞联合射频消融30例,另纳入11例新诊断未治疗肝细胞癌对照(男/女6/5,平均年龄64岁);MRI方案包括2D MRE序列;由两名观察者在减影图像上评估肿瘤坏死程度,由一名观察者在对比增强T1加权成像上计算肿瘤强化比。
诊断标准与关键数值
- 共评估63个肝细胞癌(平均大小3.2±1.6 cm);治疗后肿瘤硬度显著低于未治疗肿瘤(3.9±1.8 vs 6.9±3.4 kPa,p=0.006),也低于肝硬度(5.3±2.2 kPa,p=0.002);肿瘤硬度与强化比相关(r=0.514,p=0.0001),与坏死百分比相关(r=-0.540,p=0.0001);放射栓塞组肿瘤硬度与强化比(r=0.636)、坏死百分比(r=-0.711)相关,均p=0.0001;坏死百分比和原生T1WI上T1信号是肿瘤硬度的显著独立预测因子(p分别为0.0001和0.001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The aim of the study was to correlate tumor stiffness (TS) measured with MR elastography (MRE) with degree of tumor enhancement and necrosis on contrast-enhanced T1-weighted imaging (CE-T1WI) in hepatocellular carcinomas (HCC) treated with Yttrium-90 radioembolization (RE) or transarterial chemoembolization plus radiofrequency ablation (TACE/RFA).
MATERIAL AND METHODS: This retrospective study was IRB-approved and the requirement for informed consent was waived. 52 patients (M/F 38/14, mean age 67 years) with HCC who underwent RE (n = 22) or TACE/RFA (n = 30) and 11 controls (M/F 6/5, mean age 64 years) with newly diagnosed untreated HCC were included. The MRI protocol included a 2D MRE sequence. TS and LS (liver stiffness) were measured on stiffness maps. Degree of tumor necrosis was assessed on subtraction images by two observers, and tumor enhancement ratios (ER) were calculated on CE-T1WI by one observer.
RESULTS: 63 HCCs (mean size 3.2 ± 1.6 cm) were evaluated. TS was significantly lower in treated vs. untreated tumors (3.9 ± 1.8 vs. 6.9 ± 3.4 kPa, p = 0.006) and also compared to LS (5.3 ± 2.2 kPa, p = 0.002). There were significant correlations between TS and each of enhancement ratios (r = 0.514, p = 0.0001), and percentage of necrosis (r = -0.540, p = 0.0001). The observed correlations were stronger in patients treated with RE (TS vs. ER, r = 0.636, TS vs. necrosis, r = -0.711, both p = 0.0001). Percentage of necrosis and T1-signal in native T1WI were significant independent predictors of TS (p = 0.0001 and 0.001, respectively).
CONCLUSION: TS measured with MRE shows a significant correlation with tumor enhancement and necrosis, especially in HCCs treated with RE.
引用
- Gordic S, Ayache JB, Kennedy P, et al. Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy. Abdom Radiol (NY). 2017. PMID: 28154910. doi:10.1007/s00261-017-1066-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。